Collegium Pharmaceutical Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Collegium Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $49.6. The average 1-year stock price forecast is 82.96% higher than the current stock price, while the lowest is $43 (+58.61%) and the highest is $60 (+121.32%).

Price Target: $49.6 (+82.96%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$43	$49.6	$48	$60
Change	+58.61%	+82.96%	+77.06%	+121.32%

Analyst Ratings

The average analyst rating for Collegium Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Feb '26	Mar '26	Apr '26	May '26	Jul '26	Aug '26
Strong Buy	3	3	3	3	2	2
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jenna Davidner Barclays	Barclays	Buy Reiterates $56 → $48	Buy	Reiterates	$56 → $48	+77.06%	Aug 19, 2026
David Amsellem Piper Sandler	Piper Sandler	Hold Reiterates $45 → $43	Hold	Reiterates	$45 → $43	+58.61%	Aug 7, 2026
Brandon Folkes H.C. Wainwright	H.C. Wainwright	Buy Reiterates $60	Buy	Reiterates	$60	+121.32%	Aug 7, 2026
Serge Belanger Needham	Needham	Buy Maintains $56 → $46	Buy	Maintains	$56 → $46	+69.68%	Aug 6, 2026
Les Sulewski Truist Financial	Truist Financial	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 15, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

836.80M

from 780.57M

7.20%

from 780.57M

Revenue Next Year

828.10M

from 836.80M

-1.04%

from 836.80M

EPS This Year

7.47

from 7.42

0.62%

from 7.42

EPS Next Year

6.77

from 7.47

-9.38%

from 7.47

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	276.87M	463.93M	566.77M	631.45M	780.57M	836.80M
Revenue Growth	-10.69%	67.57%	22.17%	11.41%	23.62%	7.20%
Gross Profit	217.80M	345.74M	471.93M	547.92M	693.64M	734.15M
Gross Margin	78.66%	74.52%	83.27%	86.77%	88.86%	87.73%
Operating Income	22.21M	38.11M	175.46M	199.63M	193.09M	450.78M
Net Income	71.52M	-25.00M	48.16M	69.19M	62.87M	108.22M
EPS	-	-	-	-	7.42	7.47
EPS Growth	-	-	-	-	15.04%	0.62%
Forward PE	4.57	4.01	5.57	4.54	6.11	3.63
Free Cash Flow	109.21M	70.53M	264.87M	362.08M	321.54M	314.75M
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	845.4M
Avg	836.8M
Low	830.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	8.3%
Avg	7.2%
Low	6.3%

EPS Forecast

Chart

EPS	2026	2027	2028
High	7.72
Avg	7.47
Low	7.28

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	4.0%
Avg	0.6%
Low	-1.9%